Lycia Therapeutics Secures $75 Million in Latest Series D Funding Round

Lycia Therapeutics secured $75 million in its latest Series D, adding another data point to the Legal, Regulatory & Compliance funding market.

Lycia Therapeutics Raises $75 million in Funding

Lycia Therapeutics Raises $75M in Series D Funding. Led by President and CEO Aetna Wun Trombley, Ph.D., Lycia Therapeutics develops modular, catalyst-driven degradation chemistries engineered to eliminate circulating or cell-surface pathogenic proteins that drive chronic autoimmune and inflammatory diseases.

Investors Behind the Funding

The round was backed by Janus Henderson Investors. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Lycia Therapeutics operates in Legal, Regulatory & Compliance. Lycia Therapeutics's financing adds to recent private-market activity.

Strategic Use of Funds

Use the funds to advance its lead cataLYTAC pipeline programs—including “LCA-0061” for food allergy and “LCA-0321” for Graves’ disease—to early Phase 1 clinical proof-of-concept.

Looking Ahead

This capital accelerates the fleet, expands reconnaissance coverage for space domain awareness and scales Starfire from constellation command to theater-scale operations,

Source reference: original announcement/article.